Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
luvometinib (FCN-159)
i
Other names:
FCN-159, FCN 159, FH1701
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
Fosun Pharma
Drug class:
MEK1 inhibitor, MEK2 inhibitor
Related drugs:
‹
cobimetinib (94)
HL-085 (12)
U0126 (10)
REC-4881 (6)
IMM-1-104 (5)
SHR7390 (3)
E6201 (1)
ABM-168 (0)
BI 847325 (0)
PD198306 (0)
TQ-B3234 (0)
cobimetinib (94)
HL-085 (12)
U0126 (10)
REC-4881 (6)
IMM-1-104 (5)
SHR7390 (3)
E6201 (1)
ABM-168 (0)
BI 847325 (0)
PD198306 (0)
TQ-B3234 (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
NRAS mutation
Melanoma
NRAS mutation
Melanoma
FCN-159
Sensitive: C2 – Inclusion Criteria
FCN-159
Sensitive
:
C2
FCN-159
Sensitive: C2 – Inclusion Criteria
FCN-159
Sensitive
:
C2
BRAF V600E
Glioma
BRAF V600E
Glioma
FCN-159
Sensitive: C2 – Inclusion Criteria
FCN-159
Sensitive
:
C2
FCN-159
Sensitive: C2 – Inclusion Criteria
FCN-159
Sensitive
:
C2
NF1 mutation
Glioma
NF1 mutation
Glioma
FCN-159
Sensitive: C3 – Early Trials
FCN-159
Sensitive
:
C3
FCN-159
Sensitive: C3 – Early Trials
FCN-159
Sensitive
:
C3
KIAA1549-BRAF fusion
Glioma
KIAA1549-BRAF fusion
Glioma
FCN-159
Sensitive: C3 – Early Trials
FCN-159
Sensitive
:
C3
FCN-159
Sensitive: C3 – Early Trials
FCN-159
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login